decoy20
decoy20: developed by 1 company · 1 clinical trial tracked.
decoy20 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect decoy20 to INDP; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could decoy20 → INDP affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Indaptus Therapeutics, Inc. (INDP) Solid Tumor, Adult | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Primary endpoint: Number of Subjects with dose-limiting toxicities (DLTs)
Interventionalopen120 targetStarted 2023-02Completion 2027-0912 sites · United StatesIndaptus Therapeutics, Inc
Frequently asked questions
Who is developing decoy20?
decoy20 is being developed by Indaptus Therapeutics, Inc..
How many clinical trials involve decoy20?
BioSniper tracks 1 clinical trial involving decoy20.